Sphingolipids

• 

  Subject Areas on Research

  • A blood spot method for detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice and humans. 
  • A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females. 
  • A genome-wide visual screen reveals a role for sphingolipids and ergosterol in cell surface delivery in yeast. 
  • Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. 
  • Abnormal lipid composition of the red cell membrane in congenital dyserythropoietic anemia type II (HEMPAS). 
  • Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. 
  • Activities of the initial enzymes of glycerolipid and sphingolipid synthesis in lung microsomes from rats exposed to air or 85% oxygen. 
  • Alteration in sphingolipid metabolism: bioassays for fumonisin- and ISP-I-like activity in tissues, cells and other matrices. 
  • Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. 
  • Alterations in β-Cell Sphingolipid Profile Associated with ER Stress and iPLA2β: Another Contributor to β-Cell Apoptosis in Type 1 Diabetes. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. 
  • Biosynthesis of long-chain (sphingoid) bases from serine by LM cells. Evidence for introduction of the 4-trans-double bond after de novo biosynthesis of N-acylsphinganine(s). 
  • Caulobacter lipid A is conditionally dispensable in the absence of fur and in the presence of anionic sphingolipids. 
  • Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. 
  • Characterizing human mesenchymal stromal cells' immune-modulatory potency using targeted lipidomic profiling of sphingolipids. 
  • Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS/MS. 
  • Convergent evolution of bacterial ceramide synthesis. 
  • Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. 
  • Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. 
  • Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. 
  • Free sphingosine formation from endogenous substrates by a liver plasma membrane system with a divalent cation dependence and a neutral pH optimum. 
  • From the editor: Homeward bound? 
  • Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. 
  • Fumonisin toxicity and sphingolipid biosynthesis. 
  • Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis. 
  • Fumonisins and other inhibitors of de novo sphingolipid biosynthesis. 
  • Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. 
  • Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. 
  • Growth-dependent regulation of cellular ceramides in human T-cells. 
  • How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? 
  • Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. 
  • In vitro toxicology of fumonisins and the mechanistic implications. 
  • Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by Fusarium moniliforme. 
  • Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. 
  • Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity. 
  • Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. 
  • Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. 
  • Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. 
  • Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. 
  • Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. 
  • Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. 
  • Mutations in sphingolipid metabolism genes are associated with ADHD. 
  • N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. 
  • Plasma membrane polarization during mating in yeast cells. 
  • Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. 
  • Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. 
  • Rvs161p and sphingolipids are required for actin repolarization following salt stress. 
  • Serine Availability Influences Mitochondrial Dynamics and Function through Lipid Metabolism. 
  • Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. 
  • Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. 
  • Sphingolipid biosynthesis by rat liver cells: effects of serine, fatty acids and lipoproteins. 
  • Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. 
  • Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. 
  • Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. 
  • Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. 
  • Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. 
  • Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. 
  • Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. 
  • Steroidogenic factor-1 is a sphingolipid binding protein. 
  • Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. 
  • Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. 
  • The effect of fumonisin B1 on developing chick embryos: correlation between de novo sphingolipid biosynthesis and gross morphological changes. 
  • Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. 
• 

  Keywords of People

  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology